308 related articles for article (PubMed ID: 30076108)
1. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
[TBL] [Abstract][Full Text] [Related]
2. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
[TBL] [Abstract][Full Text] [Related]
3. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
5. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing.
Ning MS; Klopp AH; Jhingran A; Lin LL; Eifel PJ; Vedam S; Lawyer AA; Olivieri ND; Guzman AB; Incalcaterra JR; Mesko SM; Pezzi TA; Boyce-Fappiano DR; Shaitelman SF; Frank SJ; Thaker NG
Brachytherapy; 2019; 18(4):445-452. PubMed ID: 30992185
[TBL] [Abstract][Full Text] [Related]
6. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
7. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness.
Orio PF; Nguyen PL; Buzurovic I; Cail DW; Chen YW
Brachytherapy; 2016; 15(6):701-706. PubMed ID: 27317191
[TBL] [Abstract][Full Text] [Related]
8. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
9. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
10. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
Morris WJ; Pickles T; Keyes M
Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
13. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer.
Marina O; Warner J; Ye H; Grills IS; Shah C; Wallace M; Gustafson GS; Brabbins DS; Martinez AA; Krauss DJ
Brachytherapy; 2014; 13(2):163-8. PubMed ID: 24295963
[TBL] [Abstract][Full Text] [Related]
14. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
Konski A; Watkins-Bruner D; Feigenberg S; Hanlon A; Kulkarni S; Beck JR; Horwitz EM; Pollack A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):408-15. PubMed ID: 16887291
[TBL] [Abstract][Full Text] [Related]
15. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer.
Alyamani N; Song J; van Katwyk S; Thavorn K; Renaud J; Haddad A; MacPherson M; Gaudet M
Curr Oncol; 2021 Jun; 28(4):2385-2398. PubMed ID: 34202403
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer.
Zemplényi AT; Kaló Z; Kovács G; Farkas R; Beöthe T; Bányai D; Sebestyén Z; Endrei D; Boncz I; Mangel L
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 26782759
[TBL] [Abstract][Full Text] [Related]
19. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
20. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
